InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Discover the complete record of transactions filed by BRYNJELSEN SEAN, Chief Executive Officer. Director active across 1 companies, notably Eton Pharmaceuticals, Inc.. Cumulatively, 8 reports have been logged. Total volume traded: €123k. The latest transaction was filed on 1 January 2026 — Retenue fiscale. Regulator: SEC (Form 4). All data is free.
Declarations8 total
US$65,7015,015 shares@ US$13.10090.0079% mcap29.4% of flow
Common Stock
SEC:0001437749-26-001290·
€65,7015,015 shares@ €13.10090.0079% mcap14.7% of flow
Common Stock
SEC:0001437749-26-001290:0·
US$96,5126,732 shares@ US$14.33630.012% mcap43.1% of flow
Common Stock
SEC:0001437749-25-037741·
€96,5126,732 shares@ €14.33630.012% mcap21.6% of flow
Common Stock
SEC:0001437749-25-037741:0·
€36,99710,000 shares@ €3.69970.0045% mcap16.5% of flow
Common Stock
SEC:0001493152-21-020807·
Ideal exit: 17 May 2022 (T+270)
€36,99710,000 shares@ €3.69970.0045% mcap8.3% of flow
Common Stock
SEC:0001493152-21-020807:0·
Ideal exit: 17 May 2022 (T+270)
€24,5615,000 shares@ €4.91220.0030% mcap11.0% of flow
Common Stock
SEC:0001493152-21-013513·
Ideal exit: 28 Feb 2022 (T+270)
€24,5615,000 shares@ €4.91220.0030% mcap5.5% of flow
Common Stock
SEC:0001493152-21-013513:0·
Ideal exit: 28 Feb 2022 (T+270)
8 of 8 declarations
About BRYNJELSEN SEAN
Sean Brynjelsen is the President and CEO of Eton Pharmaceuticals, Inc. He leads the company by implementing strategies aimed at developing innovative pharmaceutical solutions and meeting market needs.
